Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 6/20 | 1.00 |
| ▸ | CTSL | P07711 | 2/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.66 |
| ▸ | CTSS | P25774 | 2/20 | 0.66 |
| ▸ | PTPN13 | Q12923 | 2/20 | 0.66 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | F2R | P25116 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259082 | 0.97 | PTPRC (0.95) | PTPRCCTSLPTPN1CTSSPTPN13 | |
| SCHEMBL6264000 | 0.82 | PTPRC (1.00) | PTPRCCTSLPTPN1CTSSPTPN13 | |
| SCHEMBL6259668 | 0.80 | PTPRC (1.00) | PTPRCCTSLPTPN1CTSSPTPN13 | |
| SCHEMBL1384022 | 0.78 | PTPRC (0.63) | PTPRCCTSLPTPN1CTSSPTPN13 | |
| SCHEMBL5332281 | 0.77 | KCNK3 (0.75) | PTPRCKCNK3KCNK9PTGS1RXFP1 | |
| SCHEMBL2638776 | 0.76 | PTGS1 (0.70) | PTPRCKCNK3KCNK9PTGS1RXFP1 | |
| SCHEMBL21022150 | 0.76 | LMNA (0.66) | PTPRCKCNK3KCNK9PTGS1RXFP1 | |
| SCHEMBL12478285 | 0.76 | PTPRC (0.60) | PTPRCCTSLPTPN1CTSSPTPN13 | |
| SCHEMBL15490695 | 0.75 | ACE2 (0.68) | PTPRCCTSLPTPN1CTSSPTPN13 | |
| SCHEMBL29790411 | 0.75 | ACE2 (0.68) | PTPRCCTSLPTPN1CTSSPTPN13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242363-B1 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| US-20030207812-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207812-A1 | Cd45 inhibitors | CD74, CD2, PTPRC | PTPRC 3/4885CTSL 2041/4885PTPN1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.